Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.
about
Recent progress in West Nile virus diagnosis and vaccinationVaccines in development against West Nile virusExperimental infection of rhesus macaques and common marmosets with a European strain of West Nile virusA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsVaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virusBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondCurrent trends in West Nile virus vaccine development.Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling.Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitisTLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidateVaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus.West Nile virus: the complex biology of an emerging pathogen.West Nile virus infection and immunity.Technologies for the development of West Nile virus vaccines.Vaccines against respiratory viral pathogens for use in neonates: opportunities and challenges.An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine.A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
P2860
Q21284433-8167D928-1F81-41A2-80EA-3EAC6CBA49F0Q26999702-2E50B0E0-FD74-4C10-8610-BE0F7A24335EQ27304916-3CE18CCB-4F08-4658-90DB-2078F9055F8EQ27321020-7FE9F20A-B4D9-4330-8521-81BAA5DE6ABEQ27329490-3DA21BEE-AC7B-4DE3-9B9C-2CD8C989E7FDQ29994527-50A100AD-3E57-4049-9DE4-0E0C85E0FF49Q34788758-0E52FDF3-4A4A-4786-A195-2FA290182EF8Q35742553-B39A7BE3-883A-441F-A926-39C534201A55Q36411126-2DE4253A-5EA2-4985-957C-2400C73955EFQ37254256-32E85E93-C09B-4963-A3BF-7E2A07F1773EQ37842337-E55F2D12-02E8-4146-95DF-8D862EB0F017Q37876095-65427B34-FEBD-43A3-BDDF-BB8CA60011F3Q38074266-794388BD-C381-4B7C-A92F-6410480207C3Q38269151-C0A29535-E28F-4CB4-84D4-3CED86F35BE8Q38269845-E3821C07-179A-4FAE-B859-E15BB9F85716Q38866173-BF6A0D8C-5BB0-46A2-8167-5EE404E81657Q41218531-4282CD3E-87CB-4BF8-9FD0-E50EADE3BF79Q57299898-9BB15CC6-51EB-4918-BCA3-1E8FF71CE908
P2860
Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of RepliVAX WN, a s ...... of West Nile virus infection.
@ast
Evaluation of RepliVAX WN, a s ...... of West Nile virus infection.
@en
type
label
Evaluation of RepliVAX WN, a s ...... of West Nile virus infection.
@ast
Evaluation of RepliVAX WN, a s ...... of West Nile virus infection.
@en
prefLabel
Evaluation of RepliVAX WN, a s ...... of West Nile virus infection.
@ast
Evaluation of RepliVAX WN, a s ...... of West Nile virus infection.
@en
P2093
P2860
P50
P1476
Evaluation of RepliVAX WN, a s ...... of West Nile virus infection.
@en
P2093
Amelia P Travassos Da Rosa
Jean L Patterson
Jessica A Montalbo
Luis D Giavedoni
Melissa de la Garza
Nigel Bourne
Peter W Mason
Ricardo Carrion
Tomohiro Ishikawa
Vida L Hodara
P2860
P304
P356
10.4269/AJTMH.2010.09-0310
P407
P577
2010-06-01T00:00:00Z